An understudied type of liver cell may drive scarring in liver disease and could be a promising target for new treatments, suggests a new study by Weill Cornell Medicine investigators.
An enzyme has been discovered to play a critical role in blocking the metabolic processes that contribute to the rapid growth and spread of liver cancer, according to a new study by Weill Cornell Medicine researchers.
The hormonal shifts that occur with menopause can increase the risk of brain changes associated with Alzheimer’s disease, according to new research from Weill Cornell Medicine investigators.
A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.
Epidemiological models of COVID-19 that are used to guide policies on social distancing measures should take into account the special dynamics of the coronavirus’s spread in nursing homes and other long-term care (LTC) facilities.
Critical care physicians, infectious disease specialists and pulmonologists from Weill Cornell Medicine and NewYork-Presbyterian have published a clinical practice guide for managing severe COVID-19 in the New England Journal of Medicine.
Dr. Jim Hu, the Ronald P. Lynch Professor of Urologic Oncology at Weill Cornell Medicine, has been awarded more than $7 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for two studies on outcomes of prostate cancer biopsy and treatment.
An intensive, one-year, lifestyle-modification treatment for type 2 diabetes patients, featuring a low-calorie diet and physical exercise, resulted in a large average weight loss, and remission of diabetes for most patients, in a clinical trial led by researchers at Weill Cornell Medicine-Qatar.
Three proteins bind to chemical marks on molecular messages in cells, targeting the messages for degradation, according to researchers at Weill Cornell Medicine. The results overturn some prevailing models of how cells use chemical tags to control their genes' expression and may offer new targets for treating leukemia, which can arise when the chemical tags go awry.
In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.
A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).
A triple combination of an investigational drug that enables immune cells to infiltrate tumors, an immunotherapy drug and chemotherapy showed promising responses in patients with the most common type of metastatic pancreatic cancer, according to data from an international phase 2a clinical trial led by Weill Cornell Medicine and Beth Israel Deaconness Medical Center investigators.
In March, as the COVID-19 pandemic gained a visible foothold in New York City, Weill Cornell Medicine and NewYork-Presbyterian faced a task unlike any they had encountered before: How would they quickly establish a reliable diagnostic testing program to identify patients and healthcare workers who had been exposed to SARS-CoV-2 amid a rapidly escalating public health crisis?
Higher levels of a type of fungus in the gut are associated with better outcomes for patients with a type of inflammatory bowel disease called ulcerative colitis who are treated with gut microbes from healthy donors.
Neurologists traditionally have expected that patients who remain in coma after cardiac arrest have almost no chance of making a meaningful recovery if they fail to emerge from coma within a week.
As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.
Although COVID-19 is a threat to everyone, people of color have been hit especially hard by the virus — what has been called a “pandemic within the pandemic.”
With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.
